| abstract |
The present invention relates to crystalline forms of TRAP (tartrate-resistant purple acid phosphatase), preferably human or rat TRAP. It provides a conserved surface created by atomic structure coordination as well as special atoms suitable for the design of modulators or inhibitors of human TRAP activity. This crystalline form of activated TRAP is useful in treating diseases or degenerative conditions that result in increased bone resorption, such as tissue damage, bone metabolism disorders, osteoporosis, Alternatively, it can be used for structure-based drug design for inhibitors. |